Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Lung Neoplasms 1Lung Diseases 1Carcinoma 1

Interventions

Carboplatin 15Pemetrexed 7Paclitaxel 7pembrolizumab 4durvalumab 4osimertinib 3entinostat 3Gemcitabine 3Erlotinib Hydrochloride 3Cisplatin 3selpercatinib 2pralsetinib 2efatutazone 2atezolizumab 2Radiosurgery 2taletrectinib 1sotorasib 1repotrectinib 1patritumab 1necitumumab 1napabucasin 1ficlatuzumab 1exemestane 1cobimetinib 1ceralasertib 1cemiplimab 1camrelizumab 1alectinib 1aflutinib 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Respiratory Tract Neoplasms × ficlatuzumab × Thoracic × Clear all
NCT01039948 2015-04-08

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

AVEO Pharmaceuticals, Inc.

Phase 1/2 Completed
203 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡